IL6 and cancer: Mao et al., in a meta-analysis of 22 studies, found that the pre-treatment peripheral cytokine levels of IL-6 and IL-8, but not IFN-γ, are predictors of worse OS of cancer patients treated with immune checkpoint inhibitors [31].